NERVGEN PHARMA CORP (NGEN.CA) Stock Income Statement
TSX-V:NGEN - TSX Venture Exchange - CA64082X2032 - Common Stock - Currency: CAD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 24.93M | 17.78M | 23.54M | 12.81M | 11.20M | |||
| Research and Development | 15.67M | 8.00M | 16.57M | 6.83M | 6.13M | |||
| Selling, General, and Administrative Expenses | 9.18M | 9.63M | 6.34M | 5.94M | 5.03M | |||
| Operating Income | -24.93M | -17.78M | -23.54M | -12.81M | -11.20M | |||
| Interest Income/Expense | 926.10K | -4.61M | 2.82M | 84.70K | 9.70K | |||
| Income Before Taxes | -24.01M | -22.38M | -20.72M | -12.73M | -11.19M | |||
| Income Tax | N/A | N/A | 0.00 | N/A | N/A | |||
| Net Income | -24.01M | -22.38M | -20.72M | -12.73M | -11.19M | |||
| EBITDA | -24.85M | -17.63M | -23.42M | -12.77M | -11.16M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.36 | -0.38 | -0.39 | -0.32 | -0.35 | |||
| Non GAAP EPS | -0.35 | N/A | -0.42 | N/A | N/A | |||
| Statistics | ||||||||
All data in CAD